Insulin lispro biosimilar (Wanbang Biopharma)

重组赖脯胰岛素生物类似药（万邦医药）

Report date: 2022/01/27 14:09:25

Base Information

Drug NameInsulin lispro biosimilar (Wanbang Biopharma)
Drug Alias Name赖脯胰岛素生物仿制药（万邦医药）Recombinant insulin lispro (Wanbang Biopharma)重组赖脯胰岛素生物仿制药（万邦医药）
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsDiabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus
Original Approved Country/TerritoryMainland China
Original Approved Date2022/01/25
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesFosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeA10AB04A10AC04A10AD04
Related LinksN/A